Adrenomyeloneuropathy (AMN)
This article highlights different genetic mutations of the ABCD1 gene causing adrenomyeloneuropathy (AMN) in three male patients of Chinese ancestry. In this cohort the patients exhibited signs of a condition known as hereditary spastic paraplegia (HSP), but genetic and biochemicalexaminations revealed mutations on the ABCD1 gene rendering AMN as the definitive diagnosis. All patients exhibited symptoms between the second and third decade of life with first indication of disease being generalized weakness on the limbs and gait abnormalities. Additionally, patient 1 suffered from numbness in the lower limbs and abnormal skin pigmentation. Moreover, patient 1 and patient 2 had impairments in sensory nerves known as peripheral neuropathy though patient 3 did not exhibit signs of it but did have a mild reduced motor response. After a year, patient 2 experienced rapid disease progression accompanied by the inability to walk independently, hearing and visual loss, and eventually was bedridden needing constant care. All three patients had elevated VLCFAs, and cerebral involvement seen on their brain MRI’s while patients 1 and 2 had spinal MRI’s which showed atrophy of the thoracic section. Overall, while patients 1 and 3 had a slow disease progression patient 2 experienced a rapid progression restricting his abilities and interfering with his daily life. The aim of the study was to highlight the importance of genetic testing in order to diagnose AMN and differentiate it from other similar conditions such as HSP. Diagnosing AMN is difficult due to the complex and nonspecific symptoms enabling genetic testing as the only valid criteria for identifying AMN. Earlier and correct diagnosis is important and provides the patient with treatment options that can halt the condition’s progression.